title: Precision treatment of distinct molecular subtypes of diffuse large B-cell lymphoma: ascribing treatment based on the molecular phenotype.
abstract: Although diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, was once considered to be a single disease, novel insights into its biology have revealed that it is molecularly heterogeneous. Technologies such as gene expression profiling have revealed that DLBCL consists of at least three distinct molecular diseases that have disparate outcomes following standard therapy. These subtypes arise from different stages of B-cell differentiation and are characterized by distinct oncogenic activation mechanisms. This knowledge has led to the investigation of strategies and novel agents that have selective activity within molecular subtypes and sets the stage for an era of precision medicine in DLBCL therapeutics, where therapy can be ascribed based on molecular phenotype. This work offers the chance of improving the curability of DLBCL, particularly in the activated B-cell subtype, where standard approaches are inadequate for a high proportion of patients. See all articles in this CCR Focus section, "Paradigm Shifts in Lymphoma."
authors.affiliation: Lymphoid Malignancy Branch, National Cancer Institute, Bethesda, Maryland.
authors.forename: Kieron
authors.initials: K
authors.lastname: Dunleavy
authors.affiliation: Lymphoid Malignancy Branch, National Cancer Institute, Bethesda, Maryland.
authors.forename: Mark
authors.initials: M
authors.lastname: Roschewski
authors.affiliation: Lymphoid Malignancy Branch, National Cancer Institute, Bethesda, Maryland. wilsonw@mail.nih.gov.
authors.forename: Wyndham H
authors.initials: WH
authors.lastname: Wilson
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000378:metabolism / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic; D019254:Genes, bcl-2; D016259:Genes, myc; D018858:Germinal Center / Q000473:pathology; D006801:Humans; D008213:Lymphocyte Activation / Q000235:genetics; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics*; D010641:Phenotype; D016896:Treatment Outcome